Co-Diagnostics Earnings Call Transcripts
Fiscal Year 2025
-
Revenue declined sharply year-over-year due to lower grant income, while operating expenses rose from a non-cash impairment. Strategic expansion in India and MENA, regulatory progress, and AI innovation position the business for future growth.
-
Strategic initiatives include a planned SPAC for the Indian JV, a new MENA joint venture, and an AI business unit. Q3 revenue declined year-over-year, but losses narrowed and cash position remains strong. Multiple clinical trials and commercial launches are expected in 2026.
-
The discussion highlighted advances in multiplex PCR diagnostics, global expansion through joint ventures in India and Saudi Arabia, and the integration of AI for improved accuracy. Upcoming milestones include clinical trials, a potential SPAC for the India JV, and continued focus on affordable, scalable solutions.
-
The presentation highlighted a vision to make real-time molecular diagnostics accessible and affordable globally, leveraging proprietary multiplex PCR technology. Expansion plans include new test panels, AI-driven automation, and international growth, especially in India and emerging markets.
-
Q2 2025 saw continued progress on the point-of-care PCR platform, with all four pipeline tests set to begin clinical trials in 2025 and commercialization of the COVID-19 test targeted for mid-2026. Revenue fell sharply year-over-year, but operational efficiency improved and cash reserves remain solid.
-
Q1 2025 saw continued progress on the CODEX PCR platform, with clinical trials for key tests expected in 2025 and regulatory submissions planned in the US, India, and South Africa. Revenue and losses narrowed year-over-year, and the company maintains a strong cash position to support upcoming launches.
Fiscal Year 2024
-
Revenue declined to $3.9M in 2024, with a net loss of $37.6M, as focus shifted to advancing the PCR platform and test pipeline. Regulatory progress included withdrawing and planning to resubmit the FDA 510(k) for the COVID-19 test, while new manufacturing capacity was established in the US and India.
-
Q3 2024 revenue declined sharply year-over-year, with a net loss widening to $9.7 million. The company advanced its PCR platform and test pipeline, expanded international focus, and increased manufacturing capacity, while awaiting FDA clearance and preparing for clinical trials in 2025.
-
Q2 2024 revenue surged to $2.7M, driven by grant income, while net loss narrowed year-over-year. The company submitted its first 510(k) for an OTC PCR platform and advanced its test pipeline, with strong global market interest pending FDA clearance.